Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA1B | Q00975 | 5/20 | 0.43 |
| ▸ | PI4KA | P42356 | 4/20 | 0.42 |
| ▸ | PI4K2B | Q8TCG2 | 4/20 | 0.42 |
| ▸ | PI4K2A | Q9BTU6 | 4/20 | 0.42 |
| ▸ | PI4KB | Q9UBF8 | 4/20 | 0.42 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.38 |
| ▸ | EGFR | P00533 | 1/20 | 0.37 |
| ▸ | ACE | P12821 | 1/20 | 0.36 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.36 |
| ▸ | PTK2B | Q14289 | 1/20 | 0.36 |
| ▸ | CTSS | P25774 | 3/20 | 0.36 |
| ▸ | CTSK | P43235 | 3/20 | 0.36 |
| ▸ | CTSB | P07858 | 2/20 | 0.36 |
| ▸ | DOT1L | Q8TEK3 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3579670 | 0.86 | CACNA1B (0.42) | CACNA1BPI4KBEGFRACECTSS | |
| SCHEMBL3578046 | 0.80 | ALDH1A1 (0.44) | CACNA1BPI4KAPI4K2BPI4K2API4KB | |
| SCHEMBL5820678 | 0.74 | CTSS (0.57) | CACNA1BACECTSSCTSKCTSB | |
| SCHEMBL5820675 | 0.74 | CTSS (0.57) | CACNA1BACECTSSCTSKCTSB | |
| SCHEMBL3582279 | 0.73 | ADORA2A (0.47) | CACNA1B | |
| SCHEMBL10314815 | 0.73 | ADORA2A (0.47) | CACNA1B | |
| SCHEMBL375820 | 0.73 | CACNA1B (0.56) | CACNA1BACECTSSCTSKCTSB | |
| SCHEMBL3574189 | 0.72 | HSP90AA1 (0.37) | CACNA1B | |
| SCHEMBL21946223 | 0.72 | CACNA1B (0.51) | CACNA1BACECTSSCTSKCTSB | |
| SCHEMBL29039972 | 0.72 | CACNA1B (0.51) | CACNA1BACECTSSCTSKCTSB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8217050-B2 | Adenine derivative as inhibitors of HSP90 for the treatment of cancer | CHROMA THERAPEUTICS LIMITED (GB) | 2012-07-10 | — | — | US | disclosed |
| US-20100035901-A1 | ADENINE DERIVATIVE AS INHIBITORS OF HSP90 FOR THE TREATMENT OF CANCER | CHROMA THERAPEUTICS LTD. | 2010-02-11 | — | — | US | disclosed |
| EP-2084161-A1 | ADENINE DERIVATIVES AS INHIBITORS OF HSP90 FOR THE TREATMENT OF CANCER | Chroma Therapeutics Limited (GB) | 2009-08-05 | — | — | EP | disclosed |
| WO-2008056120-A1 | ADENINE DERIVATIVES AS INHIBITORS OF HSP90 FOR THE TREATMENT OF CANCER | CHROMA THERAPEUTICS LTD (GB) | 2008-05-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100035901-A1 | ADENINE DERIVATIVE AS INHIBITORS OF HSP90 FOR THE TREATMENT OF CANCER | HSP90AA1, HSP90AB1, HSP90B1 | CACNA1B 4810/4885PI4KA 3587/4885PI4K2B 4204/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.